Search

Displaying results 1981 - 1990 of 10000 in total
  1. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    or ocular hypertension. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  2. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Products: MOXONIDINA EG, Normohex 0,2 mg - Filmtabletten
  3. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. … A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic

  4. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287]. … Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708].

  5. Drug

    Carboprost tromethamine

    go.drugbank.com/drugs/DB00429
    ApprovedInvestigational

    A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.

  6. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing … Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant.

  7. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

    Categories: combinations of sulfonamidesProducts: ZELBORAF ® TABLETAS LACADAS DE 240 MG, ZELBORAF 240 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLET
  8. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.

    Products: ELUXAT 84 MG SERT KAPSÜL, CERDELGA® 84 MG CÁPSULA DURA
  9. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  10. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. … [A244225] Daridorexant works on orexin receptors OX1R and OX2R to block the binding of orexins, which are wake-promoting neuropeptides and endogenous ligands to these receptors.